Trial Profile
A Phase 1, First-in-Human, Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs EVT 801 (Primary)
- Indications Liver cancer; Renal cell carcinoma; Soft tissue sarcoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Kazia Therapeutics
- 13 Mar 2024 According to a Kazia Therapeutics media release, data from this study will be presented at the Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California, from 5-10 April 2024.
- 21 Feb 2024 According to a Kazia Therapeutics media release, preliminary data is anticipated in CY2024.
- 24 Oct 2023 Results (n=53) assessing VEGFR3 expression profiling by histology presented at the 48th European Society for Medical Oncology Congress